Targeting hepatocytes with liposomal interferon-alpha: effect on metallothionein gene induction

Area of Science:

• Hepatology
• Biotechnology
• Molecular Biology

Background:

• Interferon-alpha (INF-alpha) is a primary treatment for chronic hepatitis B but causes severe side effects.
• Liposomal encapsulation is a strategy to potentially mitigate INF-alpha side effects and enhance efficacy.
• Metallothionein gene (MT-IIA) expression serves as a biomarker for cellular response to INF-alpha.

Purpose of the Study:

• To evaluate the activity of free and liposome-encapsulated INF-alpha on Chang liver cells.
• To compare the effects of different liposomal formulations (DMPC, DOPE/DMPC, DOPE/DMPG) on MT-IIA gene expression.
• To assess the sustained-time effects of DMPC liposomal INF-alpha compared to free INF-alpha.

Main Methods:

• INF-alpha was encapsulated in various liposomal formulations: DMPC, DOPE/DMPC, and DOPE/DMPG.
• Chang liver cells were incubated with free or liposomal INF-alpha (100 units/ml) for 10 hours.
• Extended-time effects were studied up to 36 hours; total RNA was extracted for Northern blot analysis and densitometry of MT-IIA and beta actin mRNA.

Main Results:

• All INF-alpha formulations, free and liposomal, increased MT-IIA gene levels compared to controls.
• Free INF-alpha showed the highest induction (80.9%), followed by DOPE/DMPG (73.6%), DMPC (43.9%), and DOPE/DMPC (35.3%).
• DMPC liposomal INF-alpha exhibited sustained-time effects comparable to free INF-alpha over 36 hours.

Conclusions:

• The liposomal formulation significantly influences the level of MT-IIA mRNA expression induced by INF-alpha.
• Liposome encapsulation can modulate the cellular response to INF-alpha, affecting its therapeutic profile.
• DMPC liposomes provide a sustained release of INF-alpha, maintaining activity comparable to the non-encapsulated form.